Latest news with #MichaelMorrissey
Yahoo
15-05-2025
- Business
- Yahoo
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other firms blowing up by double digits today. Ten individual stocks soared by double digits on Wednesday, outperforming a lackluster performance among Wall Street's indices, thanks to the 90-day truce between the US and China that continued to boost investor confidence. In contrast, Wall Street's indices were mixed, with the tech-heavy Nasdaq growing 0.72 percent, followed by the S&P 500, up 0.10 percent. The Dow Jones declined by 0.21 percent. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Exelixis soared by 20.84 percent on Wednesday to finish at $44.65 each following a strong earnings performance in the first three months, coupled with a more optimistic outlook for the rest of the year. In its latest earnings release, Exelixis, Inc. (NASDAQ:EXEL) said net income expanded by 332 percent to $160 million from $37 million in the same period last year. Revenues, on the other hand, grew by 30 percent to $555 million from $425 million year-on-year, primarily due to an increase in sales volume and an increase in average net selling price. 'Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX demand, new patient starts, and revenues,' said President and CEO Michael Morrissey. Based on the strong figures, the company has raised its growth outlook for net product revenues and total revenues, both by $100 million for the full year. Overall, EXEL ranks 1st on our list of firms blowing up by double digits today. While we acknowledge the potential of EXEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXEL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other firms blowing up by double digits today. Ten individual stocks soared by double digits on Wednesday, outperforming a lackluster performance among Wall Street's indices, thanks to the 90-day truce between the US and China that continued to boost investor confidence. In contrast, Wall Street's indices were mixed, with the tech-heavy Nasdaq growing 0.72 percent, followed by the S&P 500, up 0.10 percent. The Dow Jones declined by 0.21 percent. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Exelixis soared by 20.84 percent on Wednesday to finish at $44.65 each following a strong earnings performance in the first three months, coupled with a more optimistic outlook for the rest of the year. In its latest earnings release, Exelixis, Inc. (NASDAQ:EXEL) said net income expanded by 332 percent to $160 million from $37 million in the same period last year. Revenues, on the other hand, grew by 30 percent to $555 million from $425 million year-on-year, primarily due to an increase in sales volume and an increase in average net selling price. 'Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX demand, new patient starts, and revenues,' said President and CEO Michael Morrissey. Based on the strong figures, the company has raised its growth outlook for net product revenues and total revenues, both by $100 million for the full year. Overall, EXEL ranks 1st on our list of firms blowing up by double digits today. While we acknowledge the potential of EXEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXEL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why Exelixis Stock Is Skyrocketing Today
Exelixis handily beat Q1 revenue and earnings estimates. The drugmaker also increased its full-year revenue guidance by $100 million. Exelixis could have more catalysts on the way later this year. 10 stocks we like better than Exelixis › Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening. Exelixis reported Q1 revenue of $555.4 million, up 30.6% year over year. This result handily topped the consensus revenue estimate of $503 million. The company posted net income of $159.6 million, or $0.55 per diluted share, based on generally accepted accounting principles (GAAP). Non-GAAP earnings were $179.6 million, or $0.62 per diluted share. This reflected a significant improvement from non-GAAP earnings of $52 million, or $0.17 per diluted share, in the prior-year period. It also blew past Wall Street's average Q1 adjusted earnings estimate of $0.42 per share. Investors like it anytime a company beats top- and bottom-line quarterly estimates, as Exelixis did in Q1. However, what they really loved in this case was Exelixis' full-year guidance. The company raised its full-year revenue outlook to a range of $2.25 billion to $2.35 billion from the previous forecast of between $2.15 billion and $2.25 billion. This $100 million guidance increase was the result of accelerating demand for Exelixis' flagship cancer drug, Cabometyx. Don't be surprised by further guidance hikes later this year. CEO Michael Morrissey said in the Q1 earnings press release that the company's team quickly shifted into action to launch Cabometyx in the advanced neuroendocrine tumors (NET) indication "within hours of receiving U.S. regulatory approval in late March." He added, "We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025." Exelixis could have more good news on the way as well. The company expects to report results from pivotal clinical studies evaluating zanzalintinib in treating colorectal cancer and non-clear cell renal cell carcinoma in the second half of 2025. With these near-term potential positive catalysts and continued strength for Cabometyx, I think Exelixis remains a good biotech stock for aggressive investors to buy. Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,951!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $796,353!* Now, it's worth noting Stock Advisor's total average return is 948% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy. Why Exelixis Stock Is Skyrocketing Today was originally published by The Motley Fool
